Pulse Biosciences Inc (PLSE) - Total Liabilities
Based on the latest financial reports, Pulse Biosciences Inc (PLSE) has total liabilities worth $15.32 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Pulse Biosciences Inc (PLSE) net asset momentum to track the company's year-over-year net asset growth rate.
Pulse Biosciences Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Pulse Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Pulse Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Pulse Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aygaz AS
IS:AYGAZ
|
Turkey | TL12.66 Billion |
|
Jiangsu Wujiang Rural Coml Bk
SHG:603323
|
China | CN¥220.35 Billion |
|
Orchid Island Capital Inc.
NYSE:ORC
|
USA | $11.28 Billion |
|
Westamerica Bancorporation
NASDAQ:WABC
|
USA | $5.03 Billion |
|
Herbalife Nutrition Ltd
F:HOO
|
Germany | €3.30 Billion |
|
Ipsos SA
PA:IPS
|
France | €1.42 Billion |
|
Liberty Latin America Ltd Class C
NASDAQ:LILAK
|
USA | $11.15 Billion |
|
Dalian Bio-Chem Co Ltd
SHG:603360
|
China | CN¥1.94 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Pulse Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PLSE market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pulse Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pulse Biosciences Inc (2014–2025)
The table below shows the annual total liabilities of Pulse Biosciences Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.46 Million | -12.16% |
| 2024-12-31 | $17.60 Million | +18.95% |
| 2023-12-31 | $14.79 Million | -81.54% |
| 2022-12-31 | $80.12 Million | +331.73% |
| 2021-12-31 | $18.56 Million | +0.87% |
| 2020-12-31 | $18.40 Million | +64.60% |
| 2019-12-31 | $11.18 Million | +159.59% |
| 2018-12-31 | $4.31 Million | +12.55% |
| 2017-12-31 | $3.83 Million | +276.57% |
| 2016-12-31 | $1.02 Million | +54.00% |
| 2015-12-31 | $659.76K | -63.78% |
| 2014-12-31 | $1.82 Million | -- |
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac… Read more